[{"x_label":"Diffuse hemispheric glioma  (Dataset = PBTA, Specimen = Pediatric Primary and Relapse Tumors, N = 28)","specimen_descriptor_fill":"Pediatric Primary and Relapse Tumors","box_sample_count":28,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"PBTA","Disease":"Diffuse hemispheric glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0016680","MONDO":"MONDO_0016680","GTEx_tissue_subgroup_UBERON":"","TPM_mean":4.12,"TPM_sd":7.05,"TPM_min":0.15,"TPM_25th_percentile":1,"TPM_median":2.67,"TPM_75th_percentile":4.21,"TPM_max":38.48},{"x_label":"Colon Adenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 289)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":289,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Colon Adenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1001949","MONDO":"MONDO_0002271","GTEx_tissue_subgroup_UBERON":"","TPM_mean":5.41,"TPM_sd":5.96,"TPM_min":0.69,"TPM_25th_percentile":2.95,"TPM_median":4.35,"TPM_75th_percentile":6.41,"TPM_max":77.56},{"x_label":"Glioblastoma Multiforme  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 165)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":165,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Glioblastoma Multiforme","GTEx_tissue_subgroup":"","EFO":"EFO_0000519","MONDO":"MONDO_0018177","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.8,"TPM_sd":1.34,"TPM_min":0.19,"TPM_25th_percentile":0.99,"TPM_median":1.52,"TPM_75th_percentile":2.19,"TPM_max":9.49},{"x_label":"Hepatocellular Carcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 371)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":371,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Hepatocellular Carcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000182","MONDO":"MONDO_0007256","GTEx_tissue_subgroup_UBERON":"","TPM_mean":0.82,"TPM_sd":0.85,"TPM_min":0.04,"TPM_25th_percentile":0.28,"TPM_median":0.53,"TPM_75th_percentile":1.01,"TPM_max":5.44},{"x_label":"Low-grade glioma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 521)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":521,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Low-grade glioma","GTEx_tissue_subgroup":"","EFO":"MONDO_0021637","MONDO":"MONDO_0021637","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.05,"TPM_sd":1.35,"TPM_min":0.07,"TPM_25th_percentile":0.36,"TPM_median":0.58,"TPM_75th_percentile":1.14,"TPM_max":11.25},{"x_label":"Lung Adenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 512)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":512,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Lung Adenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000571","MONDO":"MONDO_0005061","GTEx_tissue_subgroup_UBERON":"","TPM_mean":2.34,"TPM_sd":2.05,"TPM_min":0.2,"TPM_25th_percentile":1.19,"TPM_median":1.75,"TPM_75th_percentile":2.76,"TPM_max":25.25},{"x_label":"Ovarian Serous Cystadenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 378)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":378,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Ovarian Serous Cystadenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_1000043","MONDO":"MONDO_0006046","GTEx_tissue_subgroup_UBERON":"","TPM_mean":1.97,"TPM_sd":1.37,"TPM_min":0.23,"TPM_25th_percentile":1.06,"TPM_median":1.63,"TPM_75th_percentile":2.48,"TPM_max":11.78},{"x_label":"Rectum Adenocarcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 93)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":93,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Rectum Adenocarcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0005631","MONDO":"MONDO_0002169","GTEx_tissue_subgroup_UBERON":"","TPM_mean":5.39,"TPM_sd":2.87,"TPM_min":0.45,"TPM_25th_percentile":3.14,"TPM_median":4.65,"TPM_75th_percentile":7.55,"TPM_max":13.95},{"x_label":"Sarcoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 261)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":261,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Sarcoma","GTEx_tissue_subgroup":"","EFO":"EFO_0000691","MONDO":"MONDO_0005089","GTEx_tissue_subgroup_UBERON":"","TPM_mean":3.54,"TPM_sd":3.03,"TPM_min":0.05,"TPM_25th_percentile":1.58,"TPM_median":2.53,"TPM_75th_percentile":4.62,"TPM_max":18.43},{"x_label":"Uterine Corpus Endometrial Carcinoma  (Dataset = TCGA, Specimen = TCGA Primary and Relapse Tumors, N = 179)","specimen_descriptor_fill":"TCGA Primary and Relapse Tumors","box_sample_count":179,"Gene_Ensembl_ID":"ENSG00000139618","Gene_symbol":"BRCA2","PMTL":"Relevant Molecular Target (PMTL version 3.1)","Dataset":"TCGA","Disease":"Uterine Corpus Endometrial Carcinoma","GTEx_tissue_subgroup":"","EFO":"EFO_0007532","MONDO":"MONDO_0000553","GTEx_tissue_subgroup_UBERON":"","TPM_mean":3.06,"TPM_sd":3.34,"TPM_min":0.04,"TPM_25th_percentile":1.44,"TPM_median":2.28,"TPM_75th_percentile":3.68,"TPM_max":26.79}]